The firm maintains a fortress-like balance sheet with a current ratio of 5.23 and a minimal debt-to-equity ratio of 0.01, supporting long-term clinical development.
| Metric | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Total Current Assets | 6.9B | 4.88B | 4.12B | 2.77B | 2.54B | 2.06B | 1.54B | 654.82M | 440.06M | 107.06M | 48.26M | 69.77M | 33.73M | 22.48M | 31.57M |
| Cash & Short-Term Investments | 4.44B | 3.38B | 3.18B | 2.19B | 2.34B | 2B | 1.5B | 645.81M | 431.62M | 101.73M | 46.28M | 55.97M | 32.06M | 21.8M | 30.52M |
| Cash Only | 3.49B | 1.5B | 2.05B | 800.74M | 1.33B | 1.22B | 372.16M | 321.48M | 228.98M | 94.55M | 38.83M | 32.18M | 31.37M | 20.41M | 30.52M |
| Short-Term Investments | 948.75M | 1.88B | 1.13B | 1.39B | 1B | 779.65M | 1.13B | 324.33M | 202.64M | 7.18M | 7.45M | 28.93M | 690.44K | 1.39M | 0 |
| Accounts Receivable | 1.66B | 909.1M | 499.27M | 277.27M | 38.22M | 7.44M | 36.17M | 4.36M | 845K | 1.12M | 719K | 1.59M | 1.52M | 568.68K | 986.33K |
| Days Sales Outstanding | 145.62 | 151.5 | 148.6 | 246.39 | 28.05 | 65.85 | 168.26 | 64.71 | 7.06 | 26.37 | 35.02 | 127.47 | 149.97 | 95.08 | 246.92 |
| Inventory | 473.53M | 407.23M | 310.55M | 228.35M | 109.08M | 25.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 383.52 | 653.97 | 961.94 | 2.83K | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.31M | 3.85M | 826.64K | 637K | 0 | 1.38K | 2.65K | 1.3K |
| Total Non-Current Assets | 1.78B | 1.32B | 418.72M | 360.06M | 307.3M | 222.41M | 67.54M | 6.88M | 4.92M | 4.18M | 2M | 1.13M | 809.19K | 450.97K | 371.98K |
| Property, Plant & Equipment | 48.25M | 43.52M | 22.68M | 16.23M | 15.84M | 11.58M | 9.18M | 942.58K | 811K | 805.6K | 272.23K | 166K | 165.7K | 231.44K | 356.43K |
| Fixed Asset Turnover | 86.09x | 50.33x | 54.08x | 25.30x | 31.39x | 3.56x | 8.55x | 26.07x | 53.87x | 19.21x | 27.52x | 27.51x | 22.31x | 9.43x | 4.09x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 272.1M | 181.44M | 125.23M | 174.9M | 171.68M | 167.34M | 45.12M | 64.06K | 15.6K | 17.88K | 7.65K | 8.51K | 0 | 0 | 15.55K |
| Long-Term Investments | 89.59M | 49.7M | 47.16M | 40.48M | 53.17M | 6.31M | 2.92M | 1.14K | 1.2K | 1.05K | 1.09K | 1K | 1.38K | 1.32K | 0 |
| Other Non-Current Assets | 77.8M | 120.46M | 126.45M | 49.23M | 34.42M | 22.14M | 10.33M | 5.87M | 4.1M | 3.36M | 1.71M | 1.17M | 642.11K | 218.21K | 0 |
| Total Assets | 8.68B | 6.2B | 4.54B | 3.13B | 2.85B | 2.28B | 1.61B | 661.7M | 444.98M | 111.24M | 50.25M | 58.51M | 34.54M | 22.93M | 31.94M |
| Asset Turnover | 0.48x | 0.35x | 0.27x | 0.13x | 0.17x | 0.02x | 0.05x | 0.04x | 0.10x | 0.14x | 0.15x | 0.08x | 0.11x | 0.10x | 0.05x |
| Asset Growth % | 39.99% | 36.55% | 44.93% | 9.96% | 25.04% | 41.56% | 143.35% | 48.7% | 300.01% | 121.38% | -14.12% | 69.4% | 50.63% | -28.21% | - |
| Total Current Liabilities | 1.32B | 669.92M | 422.99M | 302.28M | 301.24M | 328.49M | 179.7M | 45.82M | 29.41M | 34M | 9.43M | 10.25M | 4.57M | 6.28M | 4.04M |
| Accounts Payable | 1.27B | 342.23M | 245.56M | 188.72M | 208.85M | 206.32M | 10.51M | 6.87M | 5.28M | 4.63M | 2.94M | 4.08M | 2.89M | 2.5M | 887.93K |
| Days Payables Outstanding | 1.03K | 549.58 | 760.63 | 2.34K | - | - | - | - | - | - | - | - | 1.03K | - | - |
| Short-Term Debt | 10.83M | 6.53M | 4.65M | 3.42M | 3.51M | 3.48M | 2.22M | 0 | 0 | 0 | 0 | 0 | 0 | 2.23M | 2.2M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 46.33M | 136.28M | 23.21M | 16.95M | 37.27M | 4.5M | 4.18M | 628.35K | 568.23K | 0 |
| Other Current Liabilities | -212.34M | 156.95M | 73.35M | 22.62M | 828K | 0 | 0 | 0 | 0 | 329.08K | 449.73K | 203.29K | 73.03K | 106.79K | 190.83K |
| Current Ratio | 5.23x | 7.29x | 9.75x | 9.18x | 8.44x | 6.26x | 8.58x | 14.29x | 14.96x | 3.15x | 5.12x | 6.81x | 7.38x | 3.58x | 7.81x |
| Quick Ratio | 4.87x | 6.68x | 9.01x | 8.42x | 8.08x | 6.19x | 8.58x | 14.29x | 14.96x | 3.15x | 5.12x | 6.81x | 7.38x | 3.58x | 7.81x |
| Cash Conversion Cycle | -497.14 | 255.89 | 349.92 | 737.91 | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 39.42M | 34.32M | 21.96M | 18.29M | 14.81M | 276.86M | 250.11M | 8.01K | 1.75M | 10.59M | 0 | 0 | -1.38K | 0 | 0 |
| Long-Term Debt | 36.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 36.33M | 32.52M | 15.35M | 9.01M | 7.96M | 6.18M | 5.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 5.16M | 8.41M | 6.44M | 1.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -33.23M | 1.8M | 1.45M | 870K | 417K | 156K | 72K | 8.01K | 1.75M | 10.59M | 0 | 0 | -1.38K | 0 | 0 |
| Total Liabilities | 1.36B | 704.24M | 444.95M | 320.56M | 316.05M | 605.36M | 429.81M | 45.83M | 31.16M | 44.59M | 9.43M | 10.25M | 4.57M | 6.28M | 4.04M |
| Total Debt | 83.49M | 39.05M | 20M | 12.43M | 11.46M | 9.66M | 7.32M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -3.41B | -1.46B | -2.03B | -788.31M | -1.32B | -1.2B | -364.84M | -321.48M | -228.98M | -94.55M | -38.83M | -39.13M | -31.37M | -20.41M | -30.52M |
| Debt / Equity | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | - | - | - | - | - | - | - | - |
| Debt / EBITDA | 0.08x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -3.15x | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | 314.23x | 39.50x | -335.83x | -331.56x | -363.73x | -1498.68x | -1264.60x | - | - | - | - | -3436.95x | -1531.96x | -4848.02x | -3464.51x |
| Total Equity | 7.32B | 5.5B | 4.1B | 2.81B | 2.53B | 1.67B | 1.18B | 615.87M | 413.81M | 66.65M | 40.76M | 60.9M | 29.97M | 16.65M | 27.9M |
| Equity Growth % | 33.19% | 34.19% | 45.63% | 11.03% | 51.38% | 41.82% | 91.66% | 48.83% | 520.87% | 63.54% | -33.08% | 103.19% | 79.99% | -40.31% | - |
| Book Value per Share | 110.91 | 84.36 | 71.67 | 51.74 | 49.62 | 36.87 | 30.57 | 17.12 | 16.81 | 3.54 | 2.59 | 3.88 | 1.91 | 1.06 | 1.78 |
| Total Shareholders' Equity | 7.32B | 5.5B | 4.1B | 2.81B | 2.53B | 1.67B | 1.18B | 615.87M | 413.81M | 66.65M | 40.76M | 60.9M | 29.97M | 16.65M | 27.9M |
| Common Stock | 7.35M | 6.98M | 6.39M | 6.64M | 6.23M | 5.74M | 5.21M | 4.12M | 3.86M | 2.12M | 1.73M | 1.91M | 643.49K | 448.33K | 439.38K |
| Retained Earnings | -279.77M | -1.57B | -2.4B | -2.11B | -1.4B | -991.93M | -383.48M | -194.01M | -120.65M | -76.24M | -55.89M | -43.54M | -35.2M | -25.6M | -12.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 73.59M | 66.71M | 72.07M | 71.72M | 465.41M | 321.21M | 53.04M | 35.4M | 14.11M | 7.88M | 5.08M | 2.89M | 1.97M | 1.56M | 540.47K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Indication expansion clinical failure
According to recent financial statements, argenx has significantly bolstered its total asset base to $8.7 billion by 2025Q4, reflecting a strategic shift from a capital-consuming R&D entity to a commercial-stage powerhouse with the financial depth required to sustain global clinical development and market expansion efforts.
The expansion of the balance sheet appears to be driven by the successful commercialization of its primary franchise, which has allowed for a substantial accumulation of cash reserves. This trajectory suggests that the company is moving toward a self-sustaining model where internal capital generation reduces the necessity for dilutive equity financing.
As reported in quarterly filings, argenx maintains a strong liquidity position with a current ratio of 5.23 in 2025Q4, providing a substantial buffer against potential shocks in the commercial launch cycle or unforeseen delays in the pipeline-in-a-product clinical development strategy for its core therapeutic assets.
The high current ratio indicates that the company is well-positioned to meet its short-term obligations without relying on external credit markets. Investors should monitor whether this liquidity remains elevated as the company potentially increases its investment in secondary indications or pursues inorganic growth opportunities.
Based on reported figures, the company's equity base has grown to $7.3 billion by 2025Q4, signaling a transition toward improved earnings quality as the firm begins to narrow its accumulated deficit, which previously reflected years of heavy, non-profitable investment in the SIMPLE Antibody platform.
The reduction in the accumulated deficit suggests that the core business is finally generating the returns necessary to offset historical R&D expenditures. This improvement in equity quality may indicate a lower risk profile for long-term shareholders as the company moves past its most capital-intensive development phase.
As indicated by the latest balance sheet data, argenx holds $272.1 million in goodwill as of 2025Q4, which warrants further investigation into the underlying valuation of past acquisitions and whether potential clinical failures in secondary indications could trigger future impairment charges that impact reported book value.
While the current goodwill figure remains a small fraction of total assets, the reliance on a single-product platform makes the company sensitive to any clinical setbacks that could diminish the perceived value of its intangible assets. Investors should remain cautious about the potential for non-cash write-downs if the pipeline-in-a-product strategy faces further regulatory or clinical hurdles.
Quick answers to the most common questions about buying ARGX stock.
As of 2025, argenx SE (ARGX) had total assets of $8.68B including $6.90B in current assets.
argenx SE (ARGX) carries total debt of $83.5M, offset by $4.44B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
argenx SE (ARGX) has total shareholders' equity (book value) of $7.32B ($110.91 book value per share). Book value represents the net worth of the company belonging to common stock holders.
argenx SE (ARGX) reported a current ratio of 5.23x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.